Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

  • The U.S. Preventive Services Task Force (USPSTF) posted a final recommendation statement and evidence summaries on screening for prostate cancer. This final recommendation provides clinicians and their patients with important new information about the benefits and harms of prostate-specific...

  • In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may have a high clinical impact on outcomes. Researchers at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrated preclinically that...

  • In the featured article from the February 2017 issue of the Journal of Nuclear Medicine, researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment. The study indicates that the new agent — a...

  • An international group of researchers report success in mice of a method of using positron emission tomography (PET) scans to track, in real time, an antibody targeting a hormone receptor pathway specifically involved in prostate cancer. This androgen receptor pathway drives development and...

  • For men with intermediate-risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects. The findings come from research presented at the 58th annual meeting of the American Society for Radiation Oncology (ASTRO)...

Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018

September 19, 2018 — Exact Imaging, makers of the ExactVu...

Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018

UCLA researchers have discovered that a combination of high doses of...

Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018

September 7, 2018 — Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-...

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis

According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate...

Exact Imaging Becomes UroGPO Imaging Partner
News | Ultrasound Imaging | August 10, 2018

August 10, 2018 — Exact Imaging announced that it has become a UroGPO Imaging Partner, joining the North American...

SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018

July 16, 2018 — Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel...

SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018

June 29, 2018 — In the battle against metastatic castrate-resistant...

Technology | Focused Ultrasound Therapy | June 19, 2018

June 19, 2018 — EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its...

Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018

June 14, 2018 — Hitachi Medical Systems Europe has been awarded the contract to supply six...

PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018

June 13, 2018 — A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine...

News | Brachytherapy Systems | June 07, 2018

June 7, 2018 — IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate...

New Studies Highlight MRI Use for Prostate Cancer Screening and Management
News | Magnetic Resonance Imaging (MRI) | May 21, 2018

May 21, 2018 — Three new studies presented at the 113th annual meeting of the American Urological Association (AUA)...

News | Radiopharmaceuticals and Tracers | May 09, 2018

May 9, 2018 — Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a...

USPSTF Updates Recommendations for Prostate Cancer Screening
News | Prostate Cancer | May 09, 2018

May 9, 2018 – The U.S. Preventive Services Task Force (USPSTF) posted a...

Combination Radiotherapy Beneficial in Treating Prostate Cancer
News | Prostate Cancer | March 27, 2018

March 27, 2018 — While there are many treatment options for men with...

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018

An Italian study featured in the March...

Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018

February 21, 2018 — Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the...

PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018

February 5, 2018 — Using nuclear...